2 results
Approved WMORecruiting
The purpose of this study is to evaluate the efficacy and safety of MDV3100, a novel potent androgen-receptor antagonist without known agonist activity, in asymptomatic or mildly symptomatic patients with progressive metastatic prostate cancer who…
Approved WMOCompleted
To compare treatment with enzaluatmide plus BI836845 with treatment with enzalutamide only.